DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,627,784 | +4.8% | 6,561 | +1.3% | 0.08% | +5.1% |
| Q2 2023 | $1,553,946 | -10.7% | 6,475 | -6.2% | 0.08% | -13.2% |
| Q1 2023 | $1,739,392 | -7.7% | 6,901 | -2.8% | 0.09% | -5.2% |
| Q4 2022 | $1,884,168 | +5.5% | 7,099 | +2.8% | 0.10% | +10.3% |
| Q3 2022 | $1,786,000 | +4.4% | 6,909 | +2.4% | 0.09% | +4.8% |
| Q2 2022 | $1,711,000 | -15.0% | 6,744 | -1.8% | 0.08% | -25.2% |
| Q1 2022 | $2,014,000 | -13.4% | 6,871 | -2.9% | 0.11% | -10.5% |
| Q4 2021 | $2,325,000 | +8.1% | 7,076 | +0.3% | 0.12% | -1.6% |
| Q3 2021 | $2,151,000 | +11.8% | 7,054 | -1.5% | 0.13% | +15.6% |
| Q2 2021 | $1,924,000 | +17.8% | 7,164 | -1.2% | 0.11% | +4.8% |
| Q1 2021 | $1,633,000 | -1.3% | 7,250 | -2.5% | 0.10% | -8.0% |
| Q4 2020 | $1,654,000 | -4.5% | 7,433 | -7.4% | 0.11% | -16.3% |
| Q3 2020 | $1,732,000 | +16.7% | 8,024 | -4.5% | 0.14% | -2.2% |
| Q2 2020 | $1,484,000 | +19.3% | 8,406 | -6.4% | 0.14% | +12.2% |
| Q1 2020 | $1,244,000 | -27.0% | 8,980 | -19.0% | 0.12% | -22.2% |
| Q4 2019 | $1,703,000 | -0.7% | 11,091 | -6.6% | 0.16% | +2.6% |
| Q3 2019 | $1,715,000 | -5.2% | 11,876 | -6.1% | 0.15% | +2.0% |
| Q2 2019 | $1,810,000 | -0.8% | 12,654 | -8.3% | 0.15% | +1.3% |
| Q1 2019 | $1,824,000 | +14.4% | 13,794 | -10.8% | 0.15% | +23.1% |
| Q4 2018 | $1,595,000 | -16.9% | 15,469 | -12.6% | 0.12% | -26.2% |
| Q3 2018 | $1,919,000 | +0.2% | 17,692 | -8.8% | 0.16% | 0.0% |
| Q2 2018 | $1,915,000 | -4.0% | 19,404 | -4.7% | 0.16% | -5.7% |
| Q1 2018 | $1,994,000 | +678.9% | 20,370 | +638.6% | 0.17% | +132.0% |
| Q4 2017 | $256,000 | -87.7% | 2,758 | -88.6% | 0.08% | -56.9% |
| Q3 2017 | $2,073,000 | -11.0% | 24,163 | -12.4% | 0.17% | -14.3% |
| Q2 2017 | $2,329,000 | -12.0% | 27,597 | -10.9% | 0.20% | -9.8% |
| Q1 2017 | $2,648,000 | +5.4% | 30,961 | -4.1% | 0.22% | -1.3% |
| Q4 2016 | $2,513,000 | -3.5% | 32,280 | -2.8% | 0.23% | -12.0% |
| Q3 2016 | $2,603,000 | -16.2% | 33,210 | -8.2% | 0.26% | -11.9% |
| Q2 2016 | $3,108,000 | -7.9% | 36,158 | +1.6% | 0.29% | -8.7% |
| Q1 2016 | $3,376,000 | – | 35,587 | – | 0.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |